© 2021 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
February 28, 2018
Eric Whitman, MD, discusses data for pembrolizumab in the frontline treatment of advanced melanoma and ongoing research with the agent in other settings of the disease.
March 29, 2017
A recent warning issued by the FDA advised that breast implants may increase an individual’s risk of developing anaplastic large cell lymphoma.
March 15, 2017
Kathleen N. Moore, MD, discusses the use of PARP inhibitors such as niraparib for the treatment of ovarian cancer – advances that could be practice changing, she says.
March 14, 2017
Helmut Schaider, MD, discusses why drug resistance in melanoma may be due to epigenetic changes and not mutation-induced changes, as well as the role of immunotherapy/targeted therapy combinations in combating resistance.